High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: A randomized multicentre study

C. Chabannon, Kenneth Cornetta, J. P. Lotz, C. Rosenfeld, M. Shlomchik, S. Yanovitch, J. P. Marolleau, G. Sledge, G. Novakovitch, Edward Srour, B. Burtness, J. Camerlo, G. Gravis, J. Lee-Fischer, C. Faucher, I. Chabbert, D. Krause, D. Maraninchi, B. Mills, L. KunkelF. Oldham, D. Blaise, P. Viens

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Seventy-one patients with poor-prognosis breast cancer were enrolled after informed consent in a multicentre randomized study to evaluate the use of selected peripheral blood CD34+ cells to support haematopoietic recovery following high-dose chemotherapy. Patients who responded to conventional chemotherapy were mobilized with chemotherapy (mainly high-dose cyclophosphamide) and/or recombinant human granulocyte colony-stimulating factor (rhG-CSF). Patients who reached the threshold of 20 CD34+ cells per μl of peripheral blood underwent apheresis and were randomized at that time to receive either unmanipulated mobilized blood cells or selected CD34+ cells. For patients in the study arm, CD34+ cells were selected from aphereses using the Isolex®300 device. Fifteen patients failed to mobilize peripheral blood progenitors and nine other patients were excluded for various reasons. Forty-seven eligible patients were randomized into two comparable groups. CD34+ cells were selected from aphereses in the study group. Haematopoietic recovery occurred at similar times in both groups. No side-effect related to the infusion of selected cells was observed. The frequency of epithelial tumour cells in aphereses was low (8 out of 42 evaluated patients), as determined by immunocytochemistry. We conclude that selected CD34+ cells safely support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.

Original languageEnglish (US)
Pages (from-to)913-921
Number of pages9
JournalBritish Journal of Cancer
Volume78
Issue number7
StatePublished - 1998
Externally publishedYes

Fingerprint

Multicenter Studies
Blood Cells
Breast Neoplasms
Drug Therapy
Blood Component Removal
Granulocyte Colony-Stimulating Factor
Informed Consent
Cyclophosphamide
Epithelial Cells
Immunohistochemistry
Equipment and Supplies
Neoplasms

Keywords

  • Bone marrow transplantation
  • Breast cancer
  • CD34
  • Haematopoietic stem cells
  • Mobilized blood cell
  • Tumour purging

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer : A randomized multicentre study. / Chabannon, C.; Cornetta, Kenneth; Lotz, J. P.; Rosenfeld, C.; Shlomchik, M.; Yanovitch, S.; Marolleau, J. P.; Sledge, G.; Novakovitch, G.; Srour, Edward; Burtness, B.; Camerlo, J.; Gravis, G.; Lee-Fischer, J.; Faucher, C.; Chabbert, I.; Krause, D.; Maraninchi, D.; Mills, B.; Kunkel, L.; Oldham, F.; Blaise, D.; Viens, P.

In: British Journal of Cancer, Vol. 78, No. 7, 1998, p. 913-921.

Research output: Contribution to journalArticle

Chabannon, C, Cornetta, K, Lotz, JP, Rosenfeld, C, Shlomchik, M, Yanovitch, S, Marolleau, JP, Sledge, G, Novakovitch, G, Srour, E, Burtness, B, Camerlo, J, Gravis, G, Lee-Fischer, J, Faucher, C, Chabbert, I, Krause, D, Maraninchi, D, Mills, B, Kunkel, L, Oldham, F, Blaise, D & Viens, P 1998, 'High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: A randomized multicentre study', British Journal of Cancer, vol. 78, no. 7, pp. 913-921.
Chabannon, C. ; Cornetta, Kenneth ; Lotz, J. P. ; Rosenfeld, C. ; Shlomchik, M. ; Yanovitch, S. ; Marolleau, J. P. ; Sledge, G. ; Novakovitch, G. ; Srour, Edward ; Burtness, B. ; Camerlo, J. ; Gravis, G. ; Lee-Fischer, J. ; Faucher, C. ; Chabbert, I. ; Krause, D. ; Maraninchi, D. ; Mills, B. ; Kunkel, L. ; Oldham, F. ; Blaise, D. ; Viens, P. / High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer : A randomized multicentre study. In: British Journal of Cancer. 1998 ; Vol. 78, No. 7. pp. 913-921.
@article{458338e03944429785d9730c0fd39bc8,
title = "High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: A randomized multicentre study",
abstract = "Seventy-one patients with poor-prognosis breast cancer were enrolled after informed consent in a multicentre randomized study to evaluate the use of selected peripheral blood CD34+ cells to support haematopoietic recovery following high-dose chemotherapy. Patients who responded to conventional chemotherapy were mobilized with chemotherapy (mainly high-dose cyclophosphamide) and/or recombinant human granulocyte colony-stimulating factor (rhG-CSF). Patients who reached the threshold of 20 CD34+ cells per μl of peripheral blood underwent apheresis and were randomized at that time to receive either unmanipulated mobilized blood cells or selected CD34+ cells. For patients in the study arm, CD34+ cells were selected from aphereses using the Isolex{\circledR}300 device. Fifteen patients failed to mobilize peripheral blood progenitors and nine other patients were excluded for various reasons. Forty-seven eligible patients were randomized into two comparable groups. CD34+ cells were selected from aphereses in the study group. Haematopoietic recovery occurred at similar times in both groups. No side-effect related to the infusion of selected cells was observed. The frequency of epithelial tumour cells in aphereses was low (8 out of 42 evaluated patients), as determined by immunocytochemistry. We conclude that selected CD34+ cells safely support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.",
keywords = "Bone marrow transplantation, Breast cancer, CD34, Haematopoietic stem cells, Mobilized blood cell, Tumour purging",
author = "C. Chabannon and Kenneth Cornetta and Lotz, {J. P.} and C. Rosenfeld and M. Shlomchik and S. Yanovitch and Marolleau, {J. P.} and G. Sledge and G. Novakovitch and Edward Srour and B. Burtness and J. Camerlo and G. Gravis and J. Lee-Fischer and C. Faucher and I. Chabbert and D. Krause and D. Maraninchi and B. Mills and L. Kunkel and F. Oldham and D. Blaise and P. Viens",
year = "1998",
language = "English (US)",
volume = "78",
pages = "913--921",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer

T2 - A randomized multicentre study

AU - Chabannon, C.

AU - Cornetta, Kenneth

AU - Lotz, J. P.

AU - Rosenfeld, C.

AU - Shlomchik, M.

AU - Yanovitch, S.

AU - Marolleau, J. P.

AU - Sledge, G.

AU - Novakovitch, G.

AU - Srour, Edward

AU - Burtness, B.

AU - Camerlo, J.

AU - Gravis, G.

AU - Lee-Fischer, J.

AU - Faucher, C.

AU - Chabbert, I.

AU - Krause, D.

AU - Maraninchi, D.

AU - Mills, B.

AU - Kunkel, L.

AU - Oldham, F.

AU - Blaise, D.

AU - Viens, P.

PY - 1998

Y1 - 1998

N2 - Seventy-one patients with poor-prognosis breast cancer were enrolled after informed consent in a multicentre randomized study to evaluate the use of selected peripheral blood CD34+ cells to support haematopoietic recovery following high-dose chemotherapy. Patients who responded to conventional chemotherapy were mobilized with chemotherapy (mainly high-dose cyclophosphamide) and/or recombinant human granulocyte colony-stimulating factor (rhG-CSF). Patients who reached the threshold of 20 CD34+ cells per μl of peripheral blood underwent apheresis and were randomized at that time to receive either unmanipulated mobilized blood cells or selected CD34+ cells. For patients in the study arm, CD34+ cells were selected from aphereses using the Isolex®300 device. Fifteen patients failed to mobilize peripheral blood progenitors and nine other patients were excluded for various reasons. Forty-seven eligible patients were randomized into two comparable groups. CD34+ cells were selected from aphereses in the study group. Haematopoietic recovery occurred at similar times in both groups. No side-effect related to the infusion of selected cells was observed. The frequency of epithelial tumour cells in aphereses was low (8 out of 42 evaluated patients), as determined by immunocytochemistry. We conclude that selected CD34+ cells safely support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.

AB - Seventy-one patients with poor-prognosis breast cancer were enrolled after informed consent in a multicentre randomized study to evaluate the use of selected peripheral blood CD34+ cells to support haematopoietic recovery following high-dose chemotherapy. Patients who responded to conventional chemotherapy were mobilized with chemotherapy (mainly high-dose cyclophosphamide) and/or recombinant human granulocyte colony-stimulating factor (rhG-CSF). Patients who reached the threshold of 20 CD34+ cells per μl of peripheral blood underwent apheresis and were randomized at that time to receive either unmanipulated mobilized blood cells or selected CD34+ cells. For patients in the study arm, CD34+ cells were selected from aphereses using the Isolex®300 device. Fifteen patients failed to mobilize peripheral blood progenitors and nine other patients were excluded for various reasons. Forty-seven eligible patients were randomized into two comparable groups. CD34+ cells were selected from aphereses in the study group. Haematopoietic recovery occurred at similar times in both groups. No side-effect related to the infusion of selected cells was observed. The frequency of epithelial tumour cells in aphereses was low (8 out of 42 evaluated patients), as determined by immunocytochemistry. We conclude that selected CD34+ cells safely support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.

KW - Bone marrow transplantation

KW - Breast cancer

KW - CD34

KW - Haematopoietic stem cells

KW - Mobilized blood cell

KW - Tumour purging

UR - http://www.scopus.com/inward/record.url?scp=0031655822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031655822&partnerID=8YFLogxK

M3 - Article

C2 - 9764583

AN - SCOPUS:0031655822

VL - 78

SP - 913

EP - 921

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -